Sermorelin
Growth Hormone-Releasing Hormone Fragment (1-29)
Sermorelin acetate is a synthetic peptide consisting of the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29). It is the shortest fully functional fragment of GHRH and has been extensively studied for its ability to stimulate natural, pulsatile growth hormone release from the pituitary. With decades of published clinical data, sermorelin remains the benchmark GHRH analog for growth hormone axis research.
Aliases: GHRH(1-29), Geref
- Research score
- 9/10
Mechanism
Sermorelin is a synthetic 29-amino acid peptide corresponding to the N-terminal segment of GHRH(1-44) that retains full biological activity at GHRH receptors. It stimulates GH gene transcription, increases pituitary GH reserve, and promotes pulsatile GH secretion by activating GHRH-R on somatotrophs via cAMP/PKA signaling. Critically, it preserves the hypothalamic-pituitary GH neuroendocrine axis (the first axis to decline with aging). By supporting pituitary function rather than bypassing it, sermorelin maintains physiological feedback mechanisms including somatostatin regulation.
Evidence note
Established — Previously FDA-approved (Geref). Extensive clinical data. Most widely prescribed peptide in anti-aging medicine via compounding pharmacies. Well-understood mechanism with decades of use.
Studies
GHRH analogs in aging
Sermorelin increased IGF-1 and improved body composition markers in older adults.
Open source · PMID 11337753Sermorelin and growth hormone deficiency
Demonstrated effective GH stimulation with preserved physiological pulsatility.
Open source · PMID 9467534Sermorelin: a better approach to management of adult-onset GH insufficiency
Sermorelin stimulates GH gene transcription, preserves the GH neuroendocrine axis, and maintains pituitary reserve — advantages over exogenous GH replacement.
Open source · PMID 19528064Sermorelin and pituitary reserve in aging
Preserves GH axis during aging better than exogenous GH. Pulsatile GH release pattern maintained, supporting physiological feedback mechanisms including somatostatin regulation.
FAQ
What is the difference between sermorelin and ipamorelin?
Sermorelin works through the GHRH receptor pathway, while ipamorelin works through the ghrelin/GHS receptor pathway — two completely different mechanisms for stimulating GH release. Sermorelin has deeper clinical data (previously FDA-approved) and is considered more established. Ipamorelin is more selective with fewer side effects. Many researchers study both together for synergistic GH release through dual-pathway stimulation.
Why was sermorelin (Geref) withdrawn from the market?
Sermorelin was FDA-approved as Geref Diagnostic in 1997 and withdrawn from the US market in 2008. The withdrawal was for commercial/business reasons (low profitability), NOT for safety concerns. Sermorelin continues to be widely prescribed through compounding pharmacies and remains the most prescribed peptide in anti-aging medicine.
When is the best time to take sermorelin?
Sermorelin is most commonly administered before bed on an empty stomach (2-3 hours after eating). This timing amplifies the natural nocturnal GH pulse that occurs during deep sleep. Food — particularly carbohydrates and fats — can blunt GH release. Some protocols include up to 1mg nightly for clinical applications.
How does it differ from HGH?
Sermorelin stimulates your pituitary to release its own GH, preserving natural pulsatile patterns and feedback loops. Exogenous HGH bypasses and suppresses this system.
Was Sermorelin FDA-approved?
Yes. Sermorelin acetate was FDA-approved as Geref® for diagnostic evaluation and treatment of growth hormone deficiency. It has one of the strongest clinical track records of any research peptide.
For research and educational use only. This content is not medical advice.